Last updated on November 2017

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma


Brief description of study

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

Detailed Study Description

The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).

Clinical Study Identifier: TX14253

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Gabrail Cancer Center Research LLC

Gabrail Cancer Center Research LLC
Canton, OH USA
  Connect »

Clinical Trials of SWLA LLC

Clinical Trials of SWLA LLC
Lake Charles, LA USA
  Connect »

Sarah Cannon Research Institute-Tennessee Oncology

Sarah Cannon Research Institute-Tennessee Oncology
Nashville, TN USA
  Connect »

Barbara Ann Karmanos Cancer Institute

Barbara Ann Karmanos Cancer Institute
Detroit, MI USA
  Connect »

Kansas City Veterans Affairs Medical ...

Kansas City Veterans Affairs Medical Center
Kansas City, MO USA
  Connect »

Florida Cancer Specialists and Research ...

Florida Cancer Specialists and Research Institute
Sarasota, FL USA
  Connect »